Targeting EGF Receptor in Ovarian Cancer with Iressa
Author Information
Author(s): Sewell J M, Macleod K G, Ritchie A, Smyth J F, Langdon S P
Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, UK
Hypothesis
Can the tyrosine kinase inhibitor ZD 1839 ('Iressa') inhibit growth of ovarian cancer cells?
Conclusion
ZD 1839 effectively inhibits the growth of ovarian cancer cells in vitro and in vivo by blocking EGF receptor activation.
Supporting Evidence
- ZD 1839 inhibited TGFα stimulated growth in ovarian cancer cell lines.
- The drug blocked EGFR phosphorylation, leading to reduced cell growth.
- In vivo studies showed significant tumor growth inhibition in a xenograft model.
Takeaway
This study shows that a drug called Iressa can help stop ovarian cancer cells from growing by blocking a specific receptor they need.
Methodology
The study tested ZD 1839 on five ovarian cancer cell lines and a xenograft model to assess its growth inhibitory effects.
Limitations
The study primarily focused on in vitro and xenograft models, which may not fully represent human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website